Literature DB >> 32506123

Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.

Stuart A Grossman1, Carlos G Romo1, Michelle A Rudek1, Jeffrey Supko2, Joy Fisher1, L Burt Nabors3, Patrick Y Wen4, David M Peereboom5, Benjamin M Ellingson6, William Elmquist7, Fred G Barker2, David Kamson1, Jann N Sarkaria8, William Timmer9, Ranjit S Bindra10, Xiaobu Ye1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32506123      PMCID： PMC7566550          DOI： 10.1093/neuonc/noaa142

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  18 in total

Review 1.  Blood-brain barrier delivery.

Authors:  William M Pardridge
Journal:  Drug Discov Today       Date:  2006-11-13       Impact factor: 7.851

2.  Quantitative Intracerebral Microdialysis Studies to Determine Unbound Extracellular Fluid Drug Concentrations in Discrete Areas of the Brain.

Authors:  Matthew R Durk
Journal:  Curr Protoc Pharmacol       Date:  2018-03

Review 3.  Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research.

Authors:  A Lasocki; F Gaillard
Journal:  AJNR Am J Neuroradiol       Date:  2019-04-04       Impact factor: 3.825

Review 4.  Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.

Authors:  Timothy P Heffron
Journal:  J Med Chem       Date:  2016-08-03       Impact factor: 7.446

5.  Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.

Authors:  Jing Li; Jianmei Wu; Xun Bao; Norissa Honea; Youming Xie; Seongho Kim; Alex Sparreboom; Nader Sanai
Journal:  Clin Cancer Res       Date:  2017-09-19       Impact factor: 12.531

6.  Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

Authors:  Stuart A Grossman; Xiaobu Ye; Steven Piantadosi; Serena Desideri; Louis B Nabors; Myrna Rosenfeld; Joy Fisher
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

7.  The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation.

Authors:  Jana Portnow; Behnam Badie; Mike Chen; An Liu; Suzette Blanchard; Timothy W Synold
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

8.  Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.

Authors:  Walter Stummer; Hanns-Jürgen Reulen; Thomas Meinel; Uwe Pichlmeier; Wiebke Schumacher; Jörg-Christian Tonn; Veit Rohde; Falk Oppel; Bernd Turowski; Christian Woiciechowsky; Kea Franz; Torsten Pietsch
Journal:  Neurosurgery       Date:  2008-03       Impact factor: 4.654

9.  Tumor Infiltration in Enhancing and Non-Enhancing Parts of Glioblastoma: A Correlation with Histopathology.

Authors:  Oliver Eidel; Sina Burth; Jan-Oliver Neumann; Pascal J Kieslich; Felix Sahm; Christine Jungk; Philipp Kickingereder; Sebastian Bickelhaupt; Sibu Mundiyanapurath; Philipp Bäumer; Wolfgang Wick; Heinz-Peter Schlemmer; Karl Kiening; Andreas Unterberg; Martin Bendszus; Alexander Radbruch
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

10.  Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center.

Authors:  Amer Haj; Christian Doenitz; Karl-Michael Schebesch; Denise Ehrensberger; Peter Hau; Kurt Putnik; Markus J Riemenschneider; Christina Wendl; Michael Gerken; Tobias Pukrop; Alexander Brawanski; Martin A Proescholdt
Journal:  Brain Sci       Date:  2017-12-25
View more
  7 in total

1.  Penetrating the brain tumor space with DNA damage response inhibitors.

Authors:  Ranjit S Bindra
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

2.  Positron emission tomography imaging of drug concentrations in the brain.

Authors:  Patrick Y Wen
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

Review 3.  Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.

Authors:  Stephen J Bagley; Shawn Kothari; Rifaquat Rahman; Eudocia Q Lee; Gavin P Dunn; Evanthia Galanis; Susan M Chang; Louis Burt Nabors; Manmeet S Ahluwalia; Roger Stupp; Minesh P Mehta; David A Reardon; Stuart A Grossman; Erik P Sulman; John H Sampson; Simon Khagi; Michael Weller; Timothy F Cloughesy; Patrick Y Wen; Mustafa Khasraw
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

Review 4.  The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.

Authors:  David R Ghasemi; Gudrun Fleischhack; Till Milde; Kristian W Pajtler
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

5.  PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook.

Authors:  Maximilian A Kirchner; Adrien Holzgreve; Matthias Brendel; Michael Orth; Viktoria C Ruf; Katja Steiger; Dennis Pötter; Lukas Gold; Marcus Unterrainer; Lena M Mittlmeier; Enio Barci; Roland E Kälin; Rainer Glass; Simon Lindner; Lena Kaiser; Jessica Maas; Louisa von Baumgarten; Harun Ilhan; Claus Belka; Johannes Notni; Peter Bartenstein; Kirsten Lauber; Nathalie L Albert
Journal:  Front Oncol       Date:  2021-11-17       Impact factor: 6.244

6.  Larger 18F-fluoroboronotyrosine (FBY) active volume beyond MRI contrast enhancement in diffuse gliomas than in circumscribed brain tumors.

Authors:  Ziren Kong; Zhu Li; Junyi Chen; Wenbin Ma; Yu Wang; Zhi Yang; Zhibo Liu
Journal:  EJNMMI Res       Date:  2022-04-18       Impact factor: 3.434

7.  Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma.

Authors:  Karisa C Schreck; Fang-Chi Hsu; Adam Berrington; Bobbie Henry-Barron; Diane Vizthum; Lindsay Blair; Eric H Kossoff; Linda Easter; Christopher T Whitlow; Peter B Barker; Mackenzie C Cervenka; Jaishri O Blakeley; Roy E Strowd
Journal:  Neurology       Date:  2021-07-07       Impact factor: 11.800
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.